Nationwide study of blood eosinophils in COPD: impact of exacerbations and corticosteroids
Authors:
Open Access
- 26 October 2026
- journal article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004269
Abstract
No abstract availableFunding Information
- Sanofi S.A., Paris, France
This publication has 33 references indexed in Scilit:
- Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological TreatmentsDrugs, 2025
- Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsNew England Journal of Medicine, 2023
- The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling studyThe Lancet Global Health, 2023
- Blood eosinophil count variability in chronic obstructive pulmonary disease and severe asthmaAllergology International, 2022
- Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPDChest, 2019
- Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trialThe Lancet Respiratory Medicine, 2019
- Changes in eosinophil count during bacterial infection: revisiting an old marker to assess the efficacy of antimicrobial therapyInternational Journal of Infectious Diseases, 2017
- Validity and underrecording of diagnosis of COPD in the Danish National Patient RegistryRespiratory Medicine, 2011
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010